Antiepileptic drugs and hormones in children

Epilepsy Research

Volumn 89, Issue 1, 2010, Pages 89-95

  Cansu, Ali ^a  

^a KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

Author keywords

Adverse effects; Antiepileptic drugs; Children; Epilepsy; Hormones

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; HORMONE; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; TOPIRAMATE; VALPROIC ACID;

ANDROGEN BLOOD LEVEL; BENIGN CHILDHOOD EPILEPSY; BODY FAT; BODY HEIGHT; BODY MASS; BODY WEIGHT; BODY WEIGHT DISORDER; BONE DISEASE; BONE MASS; BONE METABOLISM; BONE STRUCTURE; CHILD; CHRONIC DRUG ADMINISTRATION; CLINICAL TRIAL; DRUG EFFECT; DRUG WITHDRAWAL; ENDOCRINE DISEASE; ESTROGEN BLOOD LEVEL; FOLLITROPIN BLOOD LEVEL; FRACTURE; FREE LIOTHYRONINE INDEX; FREE THYROXINE INDEX; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENITAL SYSTEM; GLUCOSE HOMEOSTASIS; GROWTH REGULATION; HORMONAL REGULATION; HUMAN; HYPERANDROGENISM; INSULIN BLOOD LEVEL; LIOTHYRONINE BLOOD LEVEL; MALE SEXUAL DYSFUNCTION; MONOTHERAPY; OSSIFICATION; OSTEOPENIA; OSTEOPOROSIS; PENIS DISEASE; PRECOCIOUS PUBERTY; PRIORITY JOURNAL; PUBERTY DISORDERS; REVIEW; SIDE EFFECT; TESTIS WEIGHT; TESTOSTERONE BLOOD LEVEL; THYROID FUNCTION; THYROID HORMONE BLOOD LEVEL; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL; WEIGHT GAIN; WEIGHT REDUCTION;

ANTICONVULSANTS; BODY WEIGHT; BONE AND BONES; CHILD; EPILEPSY; HUMANS; NEUROSECRETORY SYSTEMS; REPRODUCTION; THYROID GLAND;

EID: 77950521467     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2009.09.008     Document Type: Review

References (64)

1. Anderson G.D. Pharmacogenetics and enzyme induction/inhibition properties of antiepileptic drugs. Neurology 2004, 63:S3-S8.
2. Attilakos A., Katsarou E., Prassouli A., Mastroyianni S., Voudris K., Fotinou A., Garoufi A. Thyroid function in children with epilepsy treated with sodium valproate monotherapy: a prospective study. Clin. Neuropharmacol. 2009, 32:32-34.
3. Aydin K., Serdaroglu A., Okuyaz C., Bideci A., Gucuyener K. Serum insulin, leptin, and neuropeptide y levels in epileptic children treated with valproate. J. Child Neurol. 2005, 20:848-851.
4. Benedetti M.S., Whomsley R., Baltes E., Tonner F. Alteration of thyroid hormone homeostasis by antiepileptic drugs in humans: involvement of glucuronosyltransferase induction. Eur. J. Clin. Pharmacol. 2005, 61:863-872.
5. Ben-Menachem E. Weight issues for people with epilepsy-a review. Epilepsia 2007, 48:42-45.
6. Biton V. Effect of antiepileptic drugs on bodyweight: overview and clinical implications for the treatment of epilepsy. CNS Drugs 2003, 17:781-791.
7. Caksen H., Dulger H., Cesur Y., Atas B., Tuncer O., Odabas D. Evaluation of thyroid and parathyroid functions in children receiving long-term carbamazepine therapy. Int. J. Neurosci. 2003, 113:1213-1217.
8. Cansu A., Serdaroglu A., Camurdan O., Hirfanoglu T., Bideci A., Gucuyener K. The evaluation of thyroid functions, thyroid antibodies, and thyroid volumes in children with epilepsy during short-term administration of oxcarbazepine and valproate. Epilepsia 2006, 47:1855-1859.
9. Cansu A., Giray S.G., Serdaroglu A., Erdogan D., Coskun Z.K., Korucuoglu U., Biri A.A. Effects of chronic treatment with valproate and oxcarbazepine on ovarian folliculogenesis in rats. Epilepsia 2008, 49:1192-1201.
10. Cansu A., Yesilkaya E., Serdaroglu A., Hirfanoglu T.L., Camurdan O., Gulbahar O., Gucuyener K., Cinaz P. Evaluation of bone turnover in epileptic children using oxcarbazepine. Pediatr. Neurol. 2008, 39:266-271.
11. Castro-Gago M., Novo-Rodriguez M.I., Gomez-Lado C., Rodriguez-Garcia J., Rodriguez-Segade S., Eiris-Punal J. Evolution of subclinical hypothyroidism in children treated with antiepileptic drugs. Pediatr. Neurol. 2007, 37:426-430.
12. Coppola G., Fortunato D., Auricchio G., Mainolfi C., Operto F.F., Signoriello G., Pascotto A., Salvatore M. Bone mineral density in children, adolescents, and young adults with epilepsy. Epilepsia 2009, 50:2140-2146.
13. Corman C.L., Leung N.M., Guberman A.H. Weight gain in epileptic patients during treatment with valproic acid: a retrospective study. Can. J. Neurol. Sci. 1997, 24:240-244.
14. de Vries L., Karasik A., Landau Z., Phillip M., Kiviti S., Goldberg-Stern H. Endocrine effects of valproate in adolescent girls with epilepsy. Epilepsia 2007, 48:470-477.
15. Demir E., Aysun S. Weight gain associated with valproate in childhood. Pediatr. Neurol. 2000, 22:361-364.
16. Eiris-Punal J., Del Rio-Garma M., Del Rio-Garma M.C., Lojo-Rocamonde S., Novo-Rodriguez I., Castro-Gago M. Long-term treatment of children with epilepsy with valproate or carbamazepine may cause subclinical hypothyroidism. Epilepsia 1999, 40:1761-1766.
17. El-Khayat H.A., Shatla H.M., Ali G.K., Abdulgani M.O., Tomoum H.Y., Attya H.A. Physical and hormonal profile of male sexual development in epilepsy. Epilepsia 2003, 44:447-452.
18. El-Khayat H.A., Abd El-Basset F.Z., Tomoum H.Y., Tohamy S.M., Zaky A.A., Mohamed M.S., Hakky S.M., El Barbary N.S., Nassef N.M. Physical growth and endocrinal disorders during pubertal maturation in girls with epilepsy. Epilepsia 2004, 45:1106-1115.
19. Erbayat Altay E., Serdaroglu A., Tumer L., Gucuyener K., Hasanoglu A. Evaluation of bone mineral metabolism in children receiving carbamazepine and valproic acid. J. Pediatr. Endocrinol. Metab. 2000, 13:933-939.
20. Farhat G., Yamout B., Mikati M.A., Demirjian S., Sawaya R., El-Hajj Fuleihan G. Effect of antiepileptic drugs on bone density in ambulatory patients. Neurology 2002, 58:1348-1353.
21. Feldkamp J., Becker A., Witte O.W., Scharff D., Scherbaum W.A. Long-term anticonvulsant therapy leads to low bone mineral density-evidence for direct drug effects of phenytoin and carbamazepine on human osteoblast-like cells. Exp. Clin. Endocrinol. Diabetes 2000, 108:37-43.
22. Gungor S., Yucel G., Akinci A., Tabel Y., Ozerol I.H., Yologlu S. The role of ghrelin in weight gain and growth in epileptic children using valproate. J. Child Neurol. 2007, 22:1384-1388.
23. Guo C.Y., Ronen G.M., Atkinson S.A. Long-term valproate and lamotrigine treatment may be a marker for reduced growth and bone mass in children with epilepsy. Epilepsia 2001, 42:1141-1147.
24. Hahn T.J. Bone complications of anticonvulsants. Drugs 1976, 12:201-211.
25. Hamed S.A., Hamed E.A., Kandil M.R., El-Shereef H.K., Abdellah M.M., Omar H. Serum thyroid hormone balance and lipid profile in patients with epilepsy. Epilepsy Res. 2005, 66:173-183.
26. Herzog A.G., Coleman A.E., Jacobs A.R., Klein P., Friedman M.N., Drislane F.W., Ransil B.J., Schomer D.L. Interictal EEG discharges, reproductive hormones, and menstrual disorders in epilepsy. Ann. Neurol. 2003, 54:625-637.
27. Herzog A.G. Disorders of reproduction in patients with epilepsy: primary neurological mechanisms. Seizure 2008, 17:101-110.
28. Hirfanoglu T., Serdaroglu A., Camurdan O., Cansu A., Bideci A., Cinaz P., Gucuyener K. Thyroid function and volume in epileptic children using carbamazepine, oxcarbazepine and valproate. Pediatr. Int. 2007, 49:822-826.
29. Isojarvi J.I. Serum steroid hormones and pituitary function in female epileptic patients during carbamazepine therapy. Epilepsia 1990, 31:438-445.
30. Isojarvi J.I., Laatikainen T.J., Pakarinen A.J., Juntunen K.T., Myllyla V.V. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N. Engl. J. Med. 1993, 329:1383-1388.
31. Isojarvi J.I., Repo M., Pakarinen A.J., Lukkarinen O., Myllyla V.V. Carbamazepine, phenytoin, sex hormones, and sexual function in men with epilepsy. Epilepsia 1995, 36:366-370.
32. Isojarvi J. Disorders of reproduction in patients with epilepsy: antiepileptic drug related mechanisms. Seizure 2008, 17:111-119.
33. Jensovsky J., Ruzicka E., Spackova N., Hejdukova B. Changes of event related potential and cognitive processes in patients with subclinical hypothyroidism after thyroxine treatment. Endocr. Regul. 2002, 36:115-122.
34. Kurlemann G., Benner T., Bramswig H.J. Adult height and target height in 111 boys and 98 girls treated for epilepsy during childhood. J. Child Neurol. 1997, 12:513-515.
35. Li H.F., Zou Y., Xia Z.Z., Gao F., Feng J.H., Yang C.W. Effects of topiramate on weight and metabolism in children with epilepsy. Acta Paediatr. 2009, 98:1521-1525.
36. Luef G., Abraham I., Trinka E., Alge A., Windisch J., Daxenbichler G., Unterberger I., Seppi K., Lechleitner M., Kramer G., Bauer G. Hyperandrogenism, postprandial hyperinsulinism and the risk of PCOS in a cross sectional study of women with epilepsy treated with valproate. Epilepsy Res. 2002, 48:91-102.
37. Luef G., Rauchenzauner M. Epilepsy and hormones: a critical review. Epilepsy Behav. 2009, 15:73-77.
38. Mikkonen K., Tapanainen P., Pakarinen A.J., Paivansalo M., Isojarvi J.I., Vainionpaa L.K. Serum androgen levels and testicular structure during pubertal maturation in male subjects with epilepsy. Epilepsia 2004, 45:769-776.
39. Mikkonen K., Vainionpaa L.K., Pakarinen A.J., Knip M., Jarvela I.Y., Tapanainen J.S., Isojarvi J.I. Long-term reproductive endocrine health in young women with epilepsy during puberty. Neurology 2004, 62:445-450.
40. Mikkonen K., Knip M., Pakarinen A.J., Lanning P., Isojarvi J.I., Vainionpaa L.K. Growth and lipid metabolism in girls and young women with epilepsy during pubertal maturation. Epilepsia 2005, 46:1114-1120.
41. Monzani F., Del Guerra P., Caraccio N., Pruneti C.A., Pucci E., Luisi M., Baschieri L. Subclinical hypothyroidism: neurobehavioral features and beneficial effect of l-thyroxine treatment. Clin. Invest. 1993, 71:367-371.
42. Morrell M.J., Hayes F.J., Sluss P.M., Adams J.M., Bhatt M., Ozkara C., Warnock C.R., Isojarvi J. Hyperandrogenism, ovulatory dysfunction, and polycystic ovary syndrome with valproate versus lamotrigine. Ann. Neurol. 2008, 64:200-211.
43. Nettekoven S., Strohle A., Trunz B., Wolters M., Hoffmann S., Horn R., Steinert M., Brabant G., Lichtinghagen R., Welkoborsky H.J., Tuxhorn I., Hahn A. Effects of antiepileptic drug therapy on vitamin D status and biochemical markers of bone turnover in children with epilepsy. Eur. J. Pediatr. 2008, 167:1369-1377.
44. Oner N., Kaya M., Karasalihoglu S., Karaca H., Celtik C., Tutunculer F. Bone mineral metabolism changes in epileptic children receiving valproic acid. J. Paediatr. Child Health 2004, 40:470-473.
45. Oppenheimer J.H., McPherson H.T. The syndrome of iodide-induced goiter and myxedema. Am. J. Med. 1961, 30:281-288.
46. Pack A.M., Gidal B., Vazquez B. Bone disease associated with antiepileptic drugs. Cleve. Clin. J. Med. 2004, 71:S42-S48.
47. Pack A. Bone health in people with epilepsy: is it impaired and what are the risk factors?. Seizure 2008, 17:181-186.
48. Rattya J., Vainionpaa L., Knip M., Lanning P., Isojarvi J.I. The effects of valproate, carbamazepine, and oxcarbazepine on growth and sexual maturation in girls with epilepsy. Pediatrics 1999, 103:588-593.
49. Rattya J., Pakarinen A.J., Knip M., Repo-Outakoski M., Myllyla V.V., Isojarvi J.I. Early hormonal changes during valproate or carbamazepine treatment: a 3-month study. Neurology 2001, 57:440-444.
50. Rattya J., Turkka J., Pakarinen A.J., Knip M., Kotila M.A., Lukkarinen O., Myllyla V.V., Isojarvi J.I. Reproductive effects of valproate, carbamazepine, and oxcarbazepine in men with epilepsy. Neurology 2001, 56:31-36.
51. Rauchenzauner M., Haberlandt E., Scholl-Burgi S., Karall D., Schoenherr E., Tatarczyk T., Engl J., Laimer M., Luef G., Ebenbichler C.F. Effect of valproic acid treatment on body composition, leptin and the soluble leptin receptor in epileptic children. Epilepsy Res. 2008, 80:142-149.
52. Setian N.S. Hypothyroidism in children: diagnosis and treatment. J. Pediatr. (Rio J) 2007, 83:S209-S216.
53. Specchio L.M., Cavallo L., La Neve A., Licci D., Sisto L., Olivieri G., Bratta P. Effects of chronic anticonvulsant monotherapy on endocrine system in prepubertal children with convulsive disorders Preliminary data. Boll. Soc. Ital. Biol. Sper. 1985, 61:189-194.
54. Tanaka K., Kodama S., Yokoyama S., Komatsu M., Konishi H., Momota K., Matsuo T. Thyroid function in children with long-term anticonvulsant treatment. Pediatr. Neurosci. 1987, 13:90-94.
55. Tekgul H., Serdaroglu G., Huseyinov A., Gokben S. Bone mineral status in pediatric outpatients on antiepileptic drug monotherapy. J. Child Neurol. 2006, 21:411-414.
56. Toledano R., Gil-Nagel A. Adverse effects of antiepileptic drugs. Semin. Neurol. 2008, 28:317-327.
57. Tsukahara H., Kimura K., Todoroki Y., Ohshima Y., Hiraoka M., Shigematsu Y., Tsukahara Y., Miura M., Mayumi M. Bone mineral status in ambulatory pediatric patients on long-term anti-epileptic drug therapy. Pediatr. Int. 2002, 44:247-253.
58. Vainionpaa L.K., Rattya J., Knip M., Tapanainen J.S., Pakarinen A.J., Lanning P., Tekay A., Myllyla V.V., Isojarvi J.I. Valproate-induced hyperandrogenism during pubertal maturation in girls with epilepsy. Ann. Neurol. 1999, 45:444-450.
59. Vainionpaa L.K., Mikkonen K., Rattya J., Knip M., Pakarinen A.J., Myllyla V.V., Isojarvi J.I. Thyroid function in girls with epilepsy with carbamazepine, oxcarbazepine, or valproate monotherapy and after withdrawal of medication. Epilepsia 2004, 45:197-203.
60. Verrotti A., Basciani F., Morresi S., Cutarella R., Morgese G., Chiarelli F. Serum sex hormone levels in young male patients with epilepsy receiving carbamazepine and valproic acid and after their withdrawal. Eur. J. Pediatr. 2000, 159:871-872.
61. Verrotti A., Basciani F., Morresi S., Morgese G., Chiarelli F. Thyroid hormones in epileptic children receiving carbamazepine and valproic acid. Pediatr. Neurol. 2001, 25:43-46.
62. Verrotti A., Basciani F., De Simone M., Trotta D., Morgese G., Chiarelli F. Insulin resistance in epileptic girls who gain weight after therapy with valproic acid. J. Child Neurol. 2002, 17:265-268.
63. Verrotti A., Greco R., Latini G., Morgese G., Chiarelli F. Increased bone turnover in prepubertal, pubertal, and postpubertal patients receiving carbamazepine. Epilepsia 2002, 43:1488-1492.
64. Verrotti A., Laus M., Scardapane A., Franzoni E., Chiarelli F. Thyroid hormones in children with epilepsy during long-term administration of carbamazepine and valproate. Eur. J. Endocrinol. 2009, 160:81-86.